期刊
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
卷 135, 期 3, 页码 406-416出版社
OXFORD UNIV PRESS INC
DOI: 10.1309/AJCP5BVL4FCLCGLU
关键词
Systemic lupus erythematosus; SLE; Thrombotic thrombocytopenic purpura; Antiphospholipid syndrome; Lupus anticoagulant; ADAMTS13
类别
资金
- National Institutes of Health (National Institute of Neurological Disorders and Stroke, Bethesda, MD)
- National Institute of Child Health and Human Development (Bethesda) [K12HD41648]
Severe manifestations of systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and thrombotic thrombocytopenic purpura (TTP) are characterized by multiorgan thrombotic microangiopathy. We describe reduction of ADAMTS13 activity and the development of systemic autoimmunity in all 8 children initially diagnosed with acquired noncongenital TTP during an 8.5-year period. Median age at diagnosis was 12.0 years (range, 2.6-17.3 years). ADAMTS13 activity was absent (<5%) in 6 patients; 3 patients had a detected inhibitor. SLE was diagnosed concurrently in 3 patients, and 4 patients were diagnosed within 5 years. Six of the children diagnosed with SLE had absent ADAMTS13 activity at diagnosis. In 6 patients with SLE, immune-mediated nephritis developed by 46 months. All surviving patients with SLE developed antiphospholipid antibodies, including some with a lupus anticoagulant. Patients with SLE did not have TTP recurrences once daily immunosuppressive regimens were started. An evaluation for SLE/APS is warranted in children and adolescents with reduced ADAMTS13 activity and thrombotic microangiopathy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据